Skip to content
AnalystLens

West Pharmaceutical Services 8-K Report, Corporate Update (Dec 13, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed December 13, 2024
Period End
December 9, 2024
Security
WST
In the record · 2016–202610-K1110-Q338-K118

WST filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Feb ’18Feb ’18
  2. Leadership change8-K · May ’20May ’20
  3. Leadership change8-K · Jul ’22Jul ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed December 13, 2024. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. (WST) disclosed under Item 8.01 (Other Events) in this Current Report filed December 13, 2024 that its Board of Directors approved, on December 9, 2024, a new share repurchase program authorizing the repurchase of up to 550,000 shares of its common stock.

Repurchases may be made from time to time on the open market or in privately negotiated transactions as permitted under Exchange Act Rule 10b-18, with the timing and number of shares depending on a variety of factors, including market conditions. The new program is expected to be completed by December 31, 2025. The filing states that the company's previously authorized share repurchase program is expected to expire by December 31, 2024, so the new authorization is set to take effect as the prior one winds down.

The filing contains no financial statements or results. Its only exhibit is the Inline XBRL cover page (Exhibit 104) for the Form 8-K dated December 9, 2024.

02—Key points

Key Highlights

  1. Board approved a new share repurchase program on December 9, 2024, authorizing repurchases of up to 550,000 shares of common stock.
  2. Repurchases may occur on the open market or in privately negotiated transactions, as permitted under Exchange Act Rule 10b-18.
  3. Timing and volume of repurchases will depend on a variety of factors, including market conditions.
  4. The new program is expected to be completed by December 31, 2025.
  5. The previously authorized repurchase program is expected to expire by December 31, 2024.
  6. The filing is limited to Item 8.01 (Other Events) and Item 9.01 with an Inline XBRL cover page exhibit; it contains no financial statements or operating results.

03—Questions

Frequently Asked Questions

  1. How many shares is West Pharmaceutical authorized to repurchase under the new program?

    The Board of Directors approved a program authorizing the repurchase of up to 550,000 shares of the company's common stock.

  2. How and where can the company buy back its shares?

    Repurchases may be made from time to time on the open market or in privately negotiated transactions, as permitted under Exchange Act Rule 10b-18.

  3. When is the new repurchase program expected to be completed?

    The program is expected to be completed by December 31, 2025.

  4. What happens to the previous repurchase authorization?

    The company's previously authorized share repurchase program is expected to expire by December 31, 2024.

  5. Does this filing disclose financial results?

    No. The filing reports only the share repurchase authorization under Item 8.01 and includes an Inline XBRL cover page exhibit; it contains no financial statements or operating results.

04—Continue

← View all 8-K filings